|Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.||Pres, CEO & Chairman||587.1k||N/A||1972|
|Dr. John F. Neylan M.D.||Exec. VP, Chief Medical Officer, & Head of Research||468.65k||N/A||1953|
|Mr. Gregory S. Curhan||Chief Financial Officer||N/A||N/A||1962|
|Ms. Jennifer J. Rhodes J.D.||Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec.||N/A||N/A||1970|
|Mr. Daniel Iazzetti||VP of HR||N/A||N/A||N/A|
|Bruce Rich||Assistant Sec.||N/A||N/A||N/A|
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
Angion Biomedica Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.